GLP-1RA – Everything you need to know! With Oviva’s Lucy Jones
There’s data at the moment that shows a million pens* are being shipped monthly through private online pharmacies in the UK
(*weight loss injectables)
Are you up to speed with the rate of change in this area?
Anna and Danielle chat to Lucy Jones, dietitian and Chief Clinical Officer at Oviva, a company transforming the way people access chronic disease care through technology. The conversation has a particular focus on GLP-1RA’s. If you’re not familiar with that term, you almost definitely will have heard of Mounjaro or Ozempic (other brands are available!)
With humour, passion, enthusiasm and eloquence, Lucy guides us through everything you need to know about GLP-1 medications, from the science, current clinical trials and new medications in the pipeline, interspersed with the human experience of using weight loss medication, all wrapped up in the value of embracing digital technology and AI, while keeping nutrition, lifestyle and behaviour change at the heart!
Listen in to find out:
- How do GLP-1RA’s work?
- What happens when people stop taking medication?
- How can people be supported in the weight maintenance phase?
- How do we make medication and nutrition support more accessible?
- What other medications are in the pipeline?
- What impact might be felt within the food industry?
- What would Lucy do if she was president for the day?!!
Lucy describes her work in the current landscape as “quite a ride to be on”. With references to clinical trials, an empassioned plea for nutrition professionals to “skill up” in the digital and AI spaces to ensure scalable solutions, and a look to the future – listen in to join this ride!
Resources referenced:
University of Oxford – Weight regain following the cessation of GLP-1 RAs for weight management: a systematic review and meta-analysis. West et al 2025: www.phc.ox.ac.uk/files/research/eco-2025-poster_samwest.pdf/@@download
Tony Blair Institute for Global Change: Anti-Obesity Medications: Faster, Broader Access Can Drive Health and Wealth in the UK
Step Up Trail: https://clinicaltrials.gov/study/NCT05646706; https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915087
Surmount 5 trial: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine
Happy listening!
Contact us if you have nutrition consultancy or recruitment requirements.